Monday, March 10, 2025
spot_img

DCGI okays Glenmark’s FabiFlu tablet to treat COVID-19 patients

Date:

Share post:

spot_img
spot_img

GUWAHATI: Finally, a silver lining even as the dark cloud of COVID-19 pandemic continues to hover of the globe. India-based Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 symptoms.

FabiFlu is the first oral Favipiravir-approved medication for the treatment of Covid-19, the company said in a statement. The drug has received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday.

“This approval comes at a time when Covid-19 cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha reportedly said.

The drug, called FabiFlu, will be marketed in some north Indian states soon. The drug will soon be available in hospitals and stores in a pack of 34 oral tables at moderately affordable price of Rs 103 per tablet.

 

spot_img
spot_img

Related articles

HYC opposes FCI’s decision to hire private security agency

SHILLONG, March 9: The Hynniewtrep Youth Council (HYC) on Friday strongly objected to the Food Corporation of India...

MSPCB gets Hulladek Honours for scientific disposal of e-waste

SHILLONG, March 9: The Meghalaya State Pollution Control Board (MSPCB) received prestigious Hulladek Honours 2025 for its exemplary...

NEDFi sanctions Rs 766 crore for over 5,000 projects in Northeast

NEW DELHI, March 9: The North Eastern Development Finance Corporation (NEDFi) has sanctioned Rs 766.47 crore and disbursed...

The language row

India's three language formula has stood the test of time. By including a local language, national language Hindi...